Related content

Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma

By                    

Experimental and Therapeutic Medicine, Vol. 3, Iss. 4, 2012-01 ,pp. : 599-602

Spandidos Publications

Access to resources Recommend Favorite

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors

By Chiorean E.   Sweeney Christopher   Youssoufian Hagop   Qin Amy   Dontabhaktuni Aruna   Loizos Nick   Nippgen Johannes   Amato Robert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 595-604

Springer Publishing Company

Access to resources Recommend Favorite

Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro

By            

Oncology Letters, Vol. 7, Iss. 1, 2014-01 ,pp. : 203-208

Spandidos Publications

Access to resources Recommend Favorite

Valproic acid, a histone deacetylase inhibitor, enhances radiosensitivity in esophageal squamous cell carcinoma

By                              

International Journal of Oncology, Vol. 40, Iss. 6, 2012-01 ,pp. : 2140-2146

Spandidos Publications

Access to resources Recommend Favorite

Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells

By    

Oncology Reports, Vol. 29, Iss. 3, 2013-01 ,pp. : 1238-1244

Spandidos Publications

Access to resources Recommend Favorite